Can you provide the last earnings date for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) last reported earnings on 2/17/2026.
HALOZYME THERAPEUTICS INC (HALO) Earnings History & Surprises
NASDAQ:HALO • US40637H1095
Current stock price
64.63 USD
+2.5 (+4.02%)
At close:
64.5 USD
-0.13 (-0.2%)
After Hours:
HALO Earnings overview
Past quarterly earnings results for HALOZYME THERAPEUTICS INC (HALO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.56
- Revenue Estimate
- 364.76M
Last Reported
Most Recent- Release Date
- Feb 17, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.24
- EPS Surprise
- -110.70%
- Revenue Surprise
- 1.13%
Beat Rate
Last 8 Quarters 88%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.24 | 2.24 | -110.70% | -119.05% | 451.767M | 446.74M | 1.13% | 51.60% |
| Q3 2025 | 1.72 | 1.66 | 3.56% | 35.43% | 354.264M | 346.72M | 2.18% | 22.12% |
| Q2 2025 | 1.54 | 1.29 | 19.26% | 69.23% | 325.719M | 291.64M | 11.69% | 40.79% |
| Q1 2025 | 1.11 | 0.97 | 14.79% | 40.51% | 264.861M | 234.78M | 12.81% | 35.22% |
| Q4 2024 | 1.26 | 1.18 | 6.64% | 53.66% | 298.008M | 294.01M | 1.36% | 29.55% |
| Q3 2024 | 1.27 | 1.00 | 26.79% | 69.33% | 290.084M | 256.08M | 13.28% | 34.28% |
| Q2 2024 | 0.91 | 0.77 | 17.68% | 22.97% | 231.353M | 209.04M | 10.67% | 4.67% |
| Q1 2024 | 0.79 | 0.71 | 11.44% | 68.09% | 195.879M | 203.77M | -3.87% | 20.81% |
| Q4 2023 | 0.82 | 0.84 | -2.55% | 70.83% | 230.039M | 235.76M | -2.43% | 26.74% |
| Q3 2023 | 0.75 | 0.72 | 3.96% | 1.35% | 216.033M | 220.43M | -1.99% | 3.37% |
| Q2 2023 | 0.74 | 0.64 | 15.31% | 39.62% | 221.038M | 203.95M | 8.38% | 45.04% |
| Q1 2023 | 0.47 | 0.49 | -3.40% | - | 162.143M | 179.02M | -9.43% | 38.23% |
| Q4 2022 | 0.48 | 0.48 | 1.02% | 14.29% | 181.5M | 195.9M | -7.35% | 77.94% |
| Q3 2022 | 0.74 | 0.52 | 41.37% | 45.10% | 209M | 194.93M | 7.22% | 80.48% |
| Q2 2022 | 0.53 | 0.51 | 3.58% | -14.52% | 152.4M | 141.56M | 7.66% | 11.65% |
| Q1 2022 | 0.47 | 0.50 | -5.96% | 27.03% | 117.3M | 130.82M | -10.33% | 31.80% |
| Q4 2021 | 0.42 | 0.41 | 1.36% | -16.00% | 102M | 102.33M | -0.32% | -16.19% |
| Q3 2021 | 0.51 | 0.43 | 18.20% | 104.00% | 115.8M | 107.74M | 7.48% | 77.34% |
| Q2 2021 | 0.62 | 0.42 | 47.85% | 226.32% | 136.5M | 106.13M | 28.62% | 147.28% |
| Q1 2021 | 0.37 | 0.32 | 14.15% | 1,025.00% | 89M | 86.576M | 2.80% | 250.39% |
| Q4 2020 | 0.50 | 0.54 | -8.15% | - | 121.7M | 122.57M | -0.71% | - |
| Q3 2020 | 0.25 | 0.20 | 25.88% | - | 65.3M | 62.12M | 5.12% | - |
| Q2 2020 | 0.19 | 0.25 | -24.33% | - | 55.2M | 68.01M | -18.84% | - |
| Q1 2020 | -0.04 | -0.02 | -89.17% | - | 25.4M | 43.821M | -42.04% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
-18.27%
Max EPS beat (4)
19.26%
Min EPS beat (4)
-110.71%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
6.95%
Max Revenue beat (4)
12.81%
Min Revenue beat (4)
1.13%
Analysis
In the last 4 quarters, HALO has beaten EPS estimates in 3 out of 4 releases
HALO has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, HALO reported -18.3% below the EPS estimates on average.
In the last 4 quarters, HALO has beaten the revenue estimates by 6.9% on average.
Related analysis
HALOZYME THERAPEUTICS INC / HALO Earnings FAQ
Can you provide information on whether HALOZYME THERAPEUTICS INC beat earnings estimates in the last quarter?
HALOZYME THERAPEUTICS INC (HALO) missed EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does HALO stock beat earnings estimates?
In the last 4 quarters, HALOZYME THERAPEUTICS INC (HALO) has beaten EPS estimates in 3 out of 4 releases.